Neurogene Inc.
NGNE•NASDAQ•Healthcare•Biotechnology

About Neurogene

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Company Information

SectorHealthcare
IndustryBiotechnology
CEORachel McMinn
Founded2003
Employees107
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.neurogene.com
Phone855 508 3568
Address
535 W 24th Street, 5th Floor New York, New York 10011 United States

Corporate Identifiers

CIK0001404644
CUSIP64135M105
ISINUS64135M1053
EIN98-0542593
SIC2834

Leadership Team & Key Executives

Dr. Rachel L. McMinn Ph.D.
Founder, Executive Chair and Chief Executive Officer
Christine Mikail Cvijic J.D.
President and Chief Financial Officer
Dr. Julie Jordan M.D.
Chief Medical Officer
Arvind Sreedharan
Senior Vice President of Business Operations
Dr. Stuart Cobb Ph.D.
Chief Scientific Officer
Donna M. Cochener-Metcalfe J.D.
Senior Vice President, General Counsel and Corporate Secretary
Dr. Effie Albanis M.D.
Senior Vice President of Clinical Affairs
Dr. Andrew E. Mulberg CPI, FAAP, M.D.
Senior Vice President of Regulatory Affairs, Quality Assurance and Quality Control
Ricardo Jimenez
Senior Vice President of Technical Operations